Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

15.63 -1.22 (-7.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 995,530
Open 16.56
Bid (Size) 15.51 (100)
Ask (Size) 16.15 (500)
Prev. Close 16.85
Today's Range 15.60 - 16.64
52wk Range 9.820 - 21.45
Shares Outstanding 103,647,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Novocure Announces Upcoming Investor Events
From Novocure
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers NovoCure (NASDAQ:NVCR) shares moved upwards by 27.7% to $19.88 during Thursday's regular session. The market value of their outstanding shares is at $1.8 billion. The company's, Q2 earnings... 
Via Benzinga

Performance

YTD
+19.1%
+19.1%
1 Month
-9.7%
-9.7%
3 Month
-9.3%
-9.3%
6 Month
+22.6%
+22.6%
1 Year
+24.0%
+24.0%

More News

Read More
The market is filled with gapping stocks in Thursday's session. ↗
Via Chartmill
News headline image
Transcript: NovoCure Q2 2026 Earnings Conference Call ↗
Via Benzinga
Topics Earnings
News headline image
NovoCure Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Novocure (NASDAQ:NVCR) Rallies 13% on Earnings Beat as High Growth Stock Nears Profitability ↗
Via Chartmill
Topics Earnings
Novocure (NASDAQ: NVCR) Q1 Revenue Beat and Path to Profitability Drive 9% Share Jump ↗
Via Chartmill
News headline image
Novocure Reports Second Quarter 2026 Financial Results
From Novocure
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
From Pomerantz LLP
Via GlobeNewswire
News headline image
Novocure to Report Second Quarter 2026 Financial Results
From Novocure
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
From Pomerantz LLP
Via GlobeNewswire
News headline image
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
From Novocure
Via Business Wire
News headline image
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
From Novocure
Via Business Wire
News headline image
CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Overlooked Stocks Set to Soar in 2026 ↗
Via The Motley Fool
News headline image
NovoCure (NVCR) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Supply Chain
Thursday's session: gap up and gap down stocks ↗
Via Chartmill

Frequently Asked Questions

Is NovoCure Limited - Ordinary Shares publicly traded?
Yes, NovoCure Limited - Ordinary Shares is publicly traded.
What exchange does NovoCure Limited - Ordinary Shares trade on?
NovoCure Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for NovoCure Limited - Ordinary Shares?
The ticker symbol for NovoCure Limited - Ordinary Shares is NVCR on the Nasdaq Stock Market
What is the current price of NovoCure Limited - Ordinary Shares?
The current price of NovoCure Limited - Ordinary Shares is 15.63
When was NovoCure Limited - Ordinary Shares last traded?
The last trade of NovoCure Limited - Ordinary Shares was at 09/09/26 04:00 PM ET
What is the market capitalization of NovoCure Limited - Ordinary Shares?
The market capitalization of NovoCure Limited - Ordinary Shares is 1.62B
How many shares of NovoCure Limited - Ordinary Shares are outstanding?
NovoCure Limited - Ordinary Shares has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.